News
The latest news from Redoxis.
Collaboration with TFS
Redoxis have entered an agreement with TFS Trial Form Support for marketing of preclinical models of Autoimmunity.
read moreContinued Funding of ProNoxis
Continued confidence and investments in Redoxis associated company ProNoxis AB With operations proceeding as planned, ProNoxis AB has secured SEK 4,0 million in a new round of financing. Signaling confidence in ProNoxis development to date, lead investor LU Bioscience has invested SEK 2,0 million and Karolinska Development SEK 2,0 million. The investment will give proof of principal in an arthritis model from lead candidates and continued lead development. LU Bio and Karolinska Development now hold 32 % and 22 % of ProNoxis, respectively....
read moreNeuriNox
Malin Hultqvist and Peter Olofsson attended the kick off meeting for the EU funded framework program NeuriNox in Geneva 23-24 january 2012. Redoxis will be part of this 5 year research program with the goal of R&D on neurodegenerative disorders to produce novel treatment for diseases like ALS and Multiple Sclerosis.
read moreRedoxis annual Christmas dinner
On Thursday 15th December, we celebrated the coming holiday with our annual Redoxis Christmas dinner. We wish all our customers and partners A Merry Christmas & A Happy New Year! and we hope to see you back in...
read moreAlbaGreen awarded for best business plan
The award for best business plan was given to AlbaGreen represented by the business developers Linus Jornevald, Anna Hallbeck and Isabel Lejonbäck at the GIBBS Business Review at Chalmers in Göteborg the 15th of December 2011, and the price was 10 000 SEK. The AlbaGreen project is a collaboration between Encubator, FHCC and Redoxis based on a plant extract with cholesterol-lowering properties. The long-term goal with the project is to implement the extract into a food product, thereby creating a cholesterol-lowering functional food with...
read morePartnering meetings
Malin Hultqvist (CSO) and Peter Olofsson (CEO) were during October representing Redoxis at BioPartnering in London and BIOEurope in Dusseldorf. Redoxis had promising meetings with more that 40 other companies and technology transfer representatives as well as discussion with large pharma companies. Redoxis will follow up these contacts with an ambition to built long lasting new relationships cross Europe and with US based companies.
read more